PHOSBRETABULIN
Tumor
Mateon TherapeuticsSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
928 Active assets in the Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi | Phase 4 | BB |
Relatlimab Bristol-Myers Squibb | Phase 2 | BB |
Inno-206 The First Affiliated Hospital of Soochow University | Phase 2/3 | BB |
Glycopyrrolate Medical College of Wisconsin | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PHOSBRETABULIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →